AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a Dividend King with over 50 consecutive annual dividend raises. The streak ...

If big pharmaceutical companies find a good Chinese drug at a low price, some experts think it may destroy American startups; others think the competition would benefit the sector. Tim Opler ...

Patients who take a common drug for high blood pressure are being urged to check the medication after its manufacturer reported that a mistake in the strength of the dose had been printed on some ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining ... the difficulty in neuroscience drug development and the inherent risks ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis. Obesity is ...

just with a large dose of anger mixed in. “This is unambiguously stupid.” He calls the big tariff chart that Trump brandished at the ceremony last Wednesday “the chart of death,” and when ...

One way to try and determine the answer is to look at chart patterns. Carter Braxton Worth of Worth Charting published a report on Wednesday last week after the close when the S&P 500 closed at ...

Column chart showing 3-day slide in European Bank Stocks Recession fears are boosting expectations for faster interest rate cuts from big central banks -- a backdrop that typically bodes ill for ...